一般社団法人日本呼吸器学会 公式サイト
日本呼吸器学会英文誌 Respiratory Investigation
日本呼吸器学会誌 増刊号 学術講演会プログラム 抄録集

Abstract

Full Text of PDF Full Text of PDF (697k)
Article in Japanese

Topics Series Obstructive Lung Disease

Therapeutics of novel bronchodilators for the treatment of chronic obstructive pulmonary disease

Akifumi Uchida  Kentaro Machida  Hiromasa Inoue 

Department of Pulmonary Medicine, Graduate School of Medical and Dental Sciences, Kagoshima University

ABSTRACT

Inhaled bronchodilators are the mainstay of current treatments for chronic obstructive pulmonary disease (COPD). Ultra-long-acting β2 agonist (ultra-LABA), which has a 24-h bronchodilating effect, rapid onset of action, and superior safety, is similar to tiotropium for the effect of bronchodilation. Ultra-LABA is one of the medicines of first choice for the treatment of COPD. New long-acting muscarinic antagonist (LAMA), which has the possibility of a greater effect for bronchodilation and a more-immediate effect than that of tiotropium, has been approved for marketing authorizations. The LABA/LAMA combination has also been developed and approved. These novel bronchodilators improve lung function, quality of life, and reduce exacerbations, and they may further improve prognosis and modify the long-term decline in lung function.

KEYWORDS

Long-acting β2 agonist (LABA)  Long-acting muscarinic antagonist (LAMA)  LABA/LAMA combination 

AJRS, 3(3): 358-365, 2014

Google Scholar